The inhibitory effect of α-MMC/MAP30, PEGylated α-MMC/MAP30, and ACV on HSV-1 glycoprotein antigen secretion glycoprotein was tested through the determination of HSV-1 glycoprotein antigen (Table 3) . The results showed a dose-dependent inhibitory effect. IC 50 was 0.67 µmol ⋅ L −1 with α-MMC, 2.94 µmol ⋅ L −1 with PEG-α-MMC, 0.47 µmol ⋅ L −1 with MAP30, 2.39 µmol ⋅ L −1 with PEG-MAP30, and 3.55 µmol ⋅ L −1 with ACV, respectively. Furthermore, IC 50 of α-MMC/MAP30 and PEG-α-MMC/MAP30 was lower than the general drug of ACV. At the same dose, the inhibitory effect on HSV-1 glycoprotein antigen secretion, glycoprotein of MAP30 was higher than that of α-MMC and PEG-MAP30 was higher than PEG-α-MMC. The MTT results showed that the ratio of cell viability can be increased on a dose-dependent feature compared with the control group when protein concentration was higher than 0.03 µmol ⋅ L -1 . But ACV did not display effects on HSV-1 inactivation. At the same dose, the ratio of cell viability with MAP30 was higher than α-MMC and PEG-MAP30 was higher than PEG-α-MMC. This indicated that both α-MMC/MAP30 and PEG-α-MMC/MAP30 had the ability of direct HSV-1 inactivation in a certain range of concentration. Additionally, the effect of inactivation was obvious with the increase of 